Provided by Tiger Trade Technology Pte. Ltd.

HANSOH PHARMA

31.540
-0.640-1.99%
Volume:9.96M
Turnover:314.16M
Market Cap:191.26B
PE:28.92
High:32.860
Open:32.380
Low:31.180
Close:32.180
52wk High:43.587
52wk Low:27.658
Shares:6.06B
HK Float Shares:6.06B
Volume Ratio:1.25
T/O Rate:0.16%
Dividend:0.50
Dividend Rate:1.57%
EPS(LYR):1.091
ROE:19.40%
ROA:9.08%
PB:4.32
PE(LYR):28.92
PS:10.26

Loading ...

Movement Alert|HANSOH PHARMA Rises 3.03% in Regular Trading, TYK2 Inhibitor HS-10374 Hits Phase III Primary Endpoints in Psoriasis Trial

Market Focus
·
Sep 21

Hansoh Pharma Says Phase 3 HS-10374 Psoriasis Trial Meets Co-Primary Endpoints

Reuters
·
Sep 21

Hansoh Pharmaceutical - Hs-10374 Meets Co-Primary Endpoints in Phase Iii Plaque Psoriasis Trial

THOMSON REUTERS
·
Sep 21

Movement Alert|HANSOH PHARMA Rises 3.09% in Regular Trading, New Drug HS-20197 Approved for Clinical Trials Targeting Solid Tumors

Market Focus
·
Sep 18

Hansoh Pharmaceutical Group Stock Climbs 1.0% in Hong Kong

Dow Jones
·
Sep 17

Hansoh Pharma Gets China Approval for Solid Tumor Drug Trials

MT Newswires Live
·
Sep 16

Hansoh Pharmaceutical - Hs-20197 for Injection Receives Clinical Trial Approval from Nmpa of China

THOMSON REUTERS
·
Sep 16

UBS Highlights Encouraging Phase 3 Data for Hansoh Pharma's Ris-Rez in Relapsed Small Cell Lung Cancer, Maintains "Buy" Rating

Stock News
·
Sep 15

Roche, GSK's Lung-Cancer Drug Candidates Show Promise in China

Dow Jones
·
Sep 14

AI Concerns, Oil Bills Blunt Asian Stock Markets

MT Newswires Live
·
Sep 14

Hansoh Pharma Reports 81.5% Response Rate in Phase Ib HS-10370 Combo Trial in First-Line KRAS G12C NSCLC

Reuters
·
Sep 14

Hansoh Pharmaceutical Group Stock Rises 5.1% in Hong Kong

Dow Jones
·
Sep 14

GSK Gains After Positive Results for Two Lung Cancer Drugs

Reuters
·
Sep 14

JPMorgan Highlights Encouraging Lung Cancer Data for Hansoh Pharma's B7-H3 ADC, Reaffirms Overweight Rating

Stock News
·
Sep 14

HK Stock Alert: Hansoh Pharma Climbs Nearly 4%; Drug Trial Shows Median Survival of 18.5 Months

Stock News
·
Sep 14

Movement Alert|HANSOH PHARMA Rises 3.12% in Regular Trading, B7-H3 ADC Phase III Data Reveals Record-Breaking Survival Benefit in Small Cell Lung Cancer

Market Focus
·
Sep 14

Hansoh Pharma Says Phase 3 Artemis-008 Study Shows Overall Survival Gain for Risvutatug Rezetecan in Relapsed SCLC

Reuters
·
Sep 13

Hansoh Pharmaceutical Says Risvutatug Rezetecan Injection Included in NMPA Priority Review

Reuters
·
Sep 11

Hansoh Pharma’s Risvutatug Rezetecan for Small-Cell Lung Cancer Enters NMPA Priority Review

Bulletin Express
·
Sep 11

Hansoh Pharma's Investigational Therapy for Small Cell Lung Cancer Granted Priority Review by Chinese Regulator

Stock News
·
Sep 11